Drug Delivery System最新文献_第6页

Cell therapeutics loaded with drug delivery system technology 载药系统技术的细胞疗法

Drug Delivery System Pub Date : 2023-01-25 DOI: 10.2745/dds.38.31

K. Kusamori, M. Nishikawa

引用次数: 0

Development of therapeutic antibodies for the treatment of infection diseases and future aspect 感染性疾病治疗性抗体的研究进展及展望

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.378

K. Haraya, Keisuke Gotanda, Rie Shiokawa, Maiko Hoshino, Chiyomi Kubo, T. Kuramochi

{"title":"Development of therapeutic antibodies for the treatment of infection diseases and future aspect","authors":"K. Haraya, Keisuke Gotanda, Rie Shiokawa, Maiko Hoshino, Chiyomi Kubo, T. Kuramochi","doi":"10.2745/dds.37.378","DOIUrl":"https://doi.org/10.2745/dds.37.378","url":null,"abstract":"Since the late 1990s, therapeutic antibodies have been developed for various oncology and immunoinflammatory diseases. To date, more than 100 therapeutic antibodies have been approved in Japan, the U.S., and Europe for these indications. In contrast, the development of antibody drugs in the field of infectious diseases has been limited so far. The recent SARS-CoV-2 pandemic has highlighted the importance of therapeutic antibodies for infectious diseases as well as the development of drug delivery systems（DDS）. This review summarizes the past development of antibody drugs for infectious diseases and provides a future perspective of how therapeutic antibodies can be developed by utilizing antibody engineering and DDS technologies.Alternate :抄録1990年代後半に、がん領域や免疫炎症性疾患領域において、抗体医薬品が画期的な治療効果を示して以降、さまざまな疾患領域において抗体医薬品の研究開発がなされ、現在までに日米欧で100品目を超える抗体医薬品が承認されている。感染症領域における抗体医薬品の開発は限られていたが、抗体工学の発展、SARS-CoV-2の感染の拡大により、感染症領域における抗体医薬品の重要性が注目されている。本稿では、これまでの感染症領域における抗体医薬品の開発と、抗体工学やDDS技術の進展に伴う今後の抗体医薬品の展望を概説する。","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48718958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

DDS for combating infectious diseases 对抗传染病的DDS

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.371

Y. Yoshioka

引用次数: 0

Silk fibroin as a medical material 医用丝素蛋白

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.448

Wei-bo Xu

引用次数: 0

Past, present and future of infectious diseases 传染病的过去、现在和未来

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.372

Y. Matsuura

引用次数: 0

Adenovirus vector vaccines 腺病毒载体疫苗

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.421

H. Mizuguchi, M. Tachibana, F. Sakurai

{"title":"Adenovirus vector vaccines","authors":"H. Mizuguchi, M. Tachibana, F. Sakurai","doi":"10.2745/dds.37.421","DOIUrl":"https://doi.org/10.2745/dds.37.421","url":null,"abstract":"Recently, importance of vaccines for treatment and prevention of emerging and re-emerging infectious diseases has been re-recognized. A replication-incompetent adenovirus（Ad） vector vaccine expressing virus antigen proteins is one of the most advanced platforms as a novel vaccine because an Ad vector vaccine can be rapidly applicable to pandemic. In this review, we describe the basic properties of an Ad vector for vaccine, in addition to the summary of the development of an Ad vector vaccine for emerging and re-emerging infectious diseases, including Coronavirus disease 2019（COVID-19）, worldwide.Alternate :抄録非増殖型アデノウイルスベクターは、in vivoへの直接投与において優れた遺伝子導入活性を示すことから、病原体由来の抗原タンパク質を発現させることにより、新興・再興感染症に対するワクチンベクターとして積極的な開発が進められてきた。最近では、新型コロナウイルス感染症（COVID-19）に対するワクチンとして、欧米中露において迅速な実用化がなされた。本稿では、アデノウイルスベクターの特性、COVID-19に対するアデノウイルスベクターワクチンの特徴、およびアデノウイルスベクターワクチンの可能性について解説する。","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45552030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of B cell-targeted vaccines utilizing immune responses against PEG 利用PEG免疫应答的B细胞靶向疫苗的研制

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.450

Taro Shimizu

引用次数: 0

Development of LONASENⓇTape, the world’s first transdermal antipsychotic drug 世界上第一种经皮抗精神病药物LONASSENⓇTape的开发

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.438

Masayasu Tanaka

引用次数: 0

Development of indigestible IgA antibody for restoring microbiome balance 用于恢复微生物组平衡的难消化IgA抗体的研制

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.395

R. Shinkura

{"title":"Development of indigestible IgA antibody for restoring microbiome balance","authors":"R. Shinkura","doi":"10.2745/dds.37.395","DOIUrl":"https://doi.org/10.2745/dds.37.395","url":null,"abstract":"Dysbiosis, especially in the gut plays a crucial role in the pathogenesis of a wide variety of diseases, including inflammatory bowel disease, colorectal cancer, cardiovascular disease, obesity, diabetes and multiple sclerosis. At mucosal surfaces, mucosal polymeric immunoglobulin A（IgA）antibodies are known to be important to regulate the gut microbiota as well as to exclude infection induced by pathogenic bacteria or virus such as influenza and SARS-CoV-2（severe acute respiratory syndrome coronavirus 2）. Since the 1970s, oral administration of IgA or IgG antibodies has been performed against infectious enteritis caused by pathogenic Escherichia coli or Clostridioides difficile. However, none of them has been successfully developed as an antibody drug up to now. Although IgA is well known to modulate the gut commensal microbiota, the therapeutic IgA drugs to treat dysbiosis has not been developed. Here, we discuss the advantages of therapeutic IgA antibodies.Alternate :抄録Dysbiosisは、健康な微生物叢と比較した微生物組成の変化であり、腸内微生物多様性の減少および微生物分類群の変化を特徴とする。腸内のdysbiosisはまた、炎症性腸疾患、結腸直腸がん、心血管疾患、肥満、糖尿病および多発性硬化症を含むさまざまな疾患の病因において重要な役割を果たすと提唱されている。腸の多量体免疫グロブリンA（IgA）抗体は、腸内微生物叢を調節するだけではなく、病原性細菌、インフルエンザやSARS-CoV-2（重症急性呼吸器症候群コロナウイルス2）などのウイルス感染を粘膜部位から排除するのに重要であることが、多くのエビデンスから示されている。1970年代以降、治療用IgAまたはIgGの経口投与試験が、主に病原性大腸菌またはディフィシル菌によって引き起こされる感染性腸炎を治療するために行われてきた。しかし、現在まで臨床応用として開発に成功したものはない。腸内病原体に対する防御機能に加えて、IgAは腸内共生微生物叢を調節して共生に導くことがよく知られているが、dysbiosisを治療するためのIgA治療薬の開発も進んでいない。本稿では、治療用IgA抗体の利点とその開発について議論する。","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42229853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Viral vector vaccines: efforts to develop vaccines against emerging infectious diseases 病毒载体疫苗:努力开发针对新发传染病的疫苗

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.429

Tokiko Watanabe

{"title":"Viral vector vaccines: efforts to develop vaccines against emerging infectious diseases","authors":"Tokiko Watanabe","doi":"10.2745/dds.37.429","DOIUrl":"https://doi.org/10.2745/dds.37.429","url":null,"abstract":"Vaccines are one of the most effective means of preventing viral infections. Since Edward Jenner invented the world's first vaccine in 1796, against smallpox, various types of vaccine have been developed, including inactivated vaccines, attenuated live vaccines, recombinant protein vaccines, viral vector vaccines and nucleic acid vaccines. Viral vector vaccines and nucleic acid vaccines （mRNA vaccines and DNA vaccines） have been developed most recently. In these vaccines, genes encoding viral proteins that serve as antigens are introduced into the body. The viral vector is an excellent vaccine delivery system that efficiently delivers antigen genes to target cells, and has been utilized for vaccine development against a variety of emerging infectious diseases, including AIDS, malaria, Ebola hemorrhagic fever, dengue fever, and most recently COVID-19. Here, we provide an overview of viral vector vaccines and discuss recent efforts to develop vaccines against emerging infectious diseases.Alternate :抄録ウイルス性感染症を予防するうえで、ワクチンは最も有効な手段の一つである。1976年、エドワード・ジェンナーが世界初のワクチンである種痘を発明して以来、さまざまなウイルス性感染症に対して、不活化ワクチン、弱毒生ワクチン、組換えタンパクワクチン、ウイルスベクターワクチン、核酸ワクチンなど、多様なプラットフォームに基づくワクチン開発が進められてきた。本稿では、数あるワクチンプラットフォームの中から、ウイルスベクターワクチンに着目して、いくつかの例をあげて概説するとともに、近年、国際的な問題となっている新興感染症に対するワクチン開発などの取り組みについても述べる。","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69200878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0